Verastem: Downgrading To Buy Based On RAMP-203 Setback In Targeting KRAS G12C NSCLC

Verastem, Inc. shifts focus to VS-7375 for KRAS G12D tumors after ending RAMP-203. Click to learn about VSTM's key catalysts ...
The American Journal of Managed Care

ICYMI: Highlights From WCLC 2025

The top content from the World Conference on Lung Cancer (WCLC) 2025 highlighted panels and abstracts presented during the ...
Medscape

Gefitinib Yields Superior Outcomes vs Chemotherapy in EGFR-Mutation-Positive NSCLC

Several reports have noted that individuals with NSCLC whose tumors are documented to contain a mutation in the EGFR receptor have a substantially greater chance of responding to small-molecule ...

ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer

Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, ...
News Medical

Zongertinib shows promising efficacy in HER2 mutation-positive NSCLC

The HER2-specific tyrosine kinase inhibitor zongertinib was well tolerated and demonstrated promising efficacy in patients with HER2 mutation-positive non-small cell lung cancer, meeting the primary ...
MedPage Today

Gregory Masters, MD, on Treating NSCLC With Driver Mutations

A year ago, ASCO released a clinical practice guideline on systemic therapy for patients with stage IV non-small cell lung cancer (NSCLC) without driver alterations. Part two has now been released, ...
Seeking Alpha

Lunit to Present AI Study on EGFR Mutation Prediction in NSCLC at AACR 2025 in Collaboration with AstraZeneca

AI-powered model predicts EGFR mutations from H&E-stained slides, demonstrating robust performance across diverse clinical settings and helping overcome barriers to molecular testing in NSCLC EGFR ...
Business Wire

Cellworks Biosimulation Predicts Chemotherapy Benefit in Osimertinib-treated NSCLC Patients with EGFR Mutations

SAN DIEGO--(BUSINESS WIRE)--Cellworks Group Inc., a leader in Personalized Therapy Decision Support and Precision Drug Development, today announced findings from a study using the Cellworks Platform ...
Business Insider

TOLREMO therapeutics Receives Two FDA Fast Track Designations for TT125-802 in Pretreated, Advanced or Metastatic NSCLC With Either an EGFR or a KRAS-G12C Mutation

TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung ...